title: Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
authors.affiliation: Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Rd, Taipei, Taiwan.
authors.forename: Yi-Hsien
authors.initials: YH
authors.lastname: Shih
authors.forename: Pin-Chun
authors.initials: PC
authors.lastname: Chen
authors.forename: Chia-Yu
authors.initials: CY
authors.lastname: Chu
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000556:secondary; D002921:Cicatrix / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D011799:Quinazolines; C583360:ficlatuzumab; D000077156:Gefitinib